Sign in
NUVL Stock Price, Chart, Stats & News
Nuvalent, Inc.
Save
Nuvalent, Inc. (NUVL) does not currently pay a dividend.
9.13B
Market cap
–
Current P/E
–
Forward P/E
NUVL chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.14% |
ROA | -30.11% |
ROE | -42.07% |
D/E | – |
Interest coverage ratio | – |
NUVL valuation
P/E | – |
P/S | – |
P/B | 5.82x |
P/CF | -26.38x |
P/FCF | -25.70x |
P/OCF | -26.38x |
PEG | 1.71x |
EV multiple | -21.70x |
About
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain.
Similar securities
Based on sector and market capitalization
Report issue